EASMIN BEGUM: Open Payments
NPI 1578236832 · GREENWICH, CT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,876 in 83 payments from 20 companies in 2025. Trend: 2023 $3,680 · 2024 $2,856 · 2025 $1,876
Food & beverage: $1,876
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 23 | $539 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 9 | $214 |
| GlaxoSmithKline, LLC. | 6 | $150 |
| Novartis Pharmaceuticals Corporation | 7 | $138 |
| Bayer Healthcare Pharmaceuticals Inc. | 5 | $111 |
| PFIZER INC. | 5 | $100 |
| Merck Sharp & Dohme LLC | 4 | $96 |
| E.R. Squibb & Sons, L.L.C. | 3 | $85 |
| Novo Nordisk Inc | 4 | $85 |
| Exact Sciences Corporation | 3 | $61 |
Products named: UBRELVY, CAPLYTA, SHINGRIX, QULIPTA, LEQVIO, Kerendia, VRAYLAR, CAMZYOS.
Industry payments across CT — which companies pay providers there.
